Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$5.95 +2.8%	$5.85	$3.79 ▼ $14.60	$326.63M	-0.88	647,673 shs	677,667 shs
FDMT 4D Molecular Therapeutics	$7.09 +3.5%	$4.93	$2.23 ▼ $17.41	$331.12M	2.83	2.57 million shs	447,469 shs
LRMR Larimar Therapeutics	$3.91 +6.0%	$3.38	$1.61 ▼ $9.50	$323.66M	0.93	1.83 million shs	1.42 million shs
WHWK Whitehawk Therapeutics	$1.74 +5.5%	$1.83	$1.39 ▼ $3.81	$77.76M	0.55	102,761 shs	70,989 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+2.76%	-2.30%	-14.51%	+9.58%	+13.12%
FDMT 4D Molecular Therapeutics	+3.50%	-2.34%	+50.53%	+103.15%	-53.32%
LRMR Larimar Therapeutics	+5.96%	-2.49%	+3.99%	+109.09%	-51.97%
WHWK Whitehawk Therapeutics	+5.45%	+8.75%	-13.43%	+173,999,900.00%	+173,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.3698 of 5 stars	3.6	2.0	0.0	0.0	1.7	1.7	0.6
FDMT 4D Molecular Therapeutics	2.059 of 5 stars	3.3	2.0	0.0	0.0	1.6	1.7	0.6
LRMR Larimar Therapeutics	2.1887 of 5 stars	3.6	1.0	0.0	0.0	2.0	3.3	0.0
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.20	Buy	$22.00	269.75% Upside
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	328.77% Upside
LRMR Larimar Therapeutics	3.10	Buy	$18.43	371.32% Upside
WHWK Whitehawk Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest WHWK, FDMT, CADL, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $18.00
8/14/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/11/2025	WHWK Whitehawk Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$1.64 per share	N/A
FDMT 4D Molecular Therapeutics	$33K	10,033.85	N/A	N/A	$9.01 per share	0.79
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A
WHWK Whitehawk Therapeutics	$25.98M	3.16	N/A	N/A	$3.65 per share	0.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$0.69	N/A	N/A	N/A	N/A	-41.00%	-26.81%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.53	N/A	N/A	N/A	-594,375.81%	-40.15%	-36.43%	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.56	N/A	N/A	N/A	N/A	-62.92%	-53.98%	10/29/2025 (Estimated)
WHWK Whitehawk Therapeutics	-$63.69M	-$0.06	N/A	∞	N/A	99.42%	-75.99%	-68.57%	N/A

Latest WHWK, FDMT, CADL, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/14/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.47	-$0.41	+$0.06	-$0.41	N/A	N/A
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million
8/7/2025	Q2 2025	WHWK Whitehawk Therapeutics	$0.49	-$0.76	-$1.25	-$0.76	$100.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	7.04	4.64
FDMT 4D Molecular Therapeutics	N/A	8.75	8.75
LRMR Larimar Therapeutics	N/A	5.46	7.48
WHWK Whitehawk Therapeutics	N/A	20.41	20.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
FDMT 4D Molecular Therapeutics	99.27%
LRMR Larimar Therapeutics	91.92%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
FDMT 4D Molecular Therapeutics	9.60%
LRMR Larimar Therapeutics	4.50%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	54.90 million	45.78 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.70 million	42.22 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable
WHWK Whitehawk Therapeutics	40	47.13 million	23.61 million	N/A

WHWK, FDMT, CADL, and LRMR Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, FDMT, CADL, and LRMR Company Descriptions

Candel Therapeutics NASDAQ:CADL

$5.95 +0.16 (+2.76%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.97 +0.02 (+0.34%)

As of 08/22/2025 06:43 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$7.09 +0.24 (+3.50%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.10 +0.01 (+0.14%)

As of 08/22/2025 07:28 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Larimar Therapeutics NASDAQ:LRMR

$3.91 +0.22 (+5.96%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 08/22/2025 07:32 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Whitehawk Therapeutics NASDAQ:WHWK

$1.74 +0.09 (+5.45%)

As of 08/22/2025 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time